Esomeprazole to Reduce Organ Failure in Sepsis

PHASE3CompletedINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 28, 2020

Primary Completion Date

August 21, 2023

Study Completion Date

August 21, 2023

Conditions
SepsisSeptic Shock
Interventions
DRUG

Esomeprazole

"160 mg of esomeprazole will be diluted in 100 ml of 0.9% sodium chloride for intravenous use for bolus.~For continuous intravenous infusion, 40 mg of esomeprazole will be reconstituted by adding 5 ml of 0.9% sodium chloride for intravenous use at a concentration of 8 mg/ml."

DRUG

Placebo

0.9% sodium chloride (same ml of the study drug)

Trial Locations (17)

20100

Humanitas Clinical Institute, Rozzano

20132

IRCCS San Raffaele Scientific Institute, Milan

Unknown

Policlinico Univeristario Campus Bio-Medico, Rome

IRCCS San Martino Istitute, Genoa

A.O.U. Mater Domini, Catanzaro

Azienda Ospedaliera Universitaria, Cagliari

USSL 10 Veneto, San Donà di Piave

Ospedale Maggiore di Lodi, Lodi

Ospedale di Merano, Merano

"Università degli Studi della Campania Luigi Vanvitelli", Napoli

AOU Pisana, Pisa

A.O.R San Carlo, Potenza

Azienda Ospedaliera San Giovanni Battista Molinette di Torino, Torino

Ospedale Santa Maria della Misericordia, Udine

Astana Medical University, Kazakhstan

Federal Clinical & Research Center for Reanimatology and Rehabilitation, Moscow

Negovskiy Reanimatology Research Institute, Moscow

All Listed Sponsors
collaborator

IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

OTHER

lead

Università Vita-Salute San Raffaele

OTHER

NCT03452865 - Esomeprazole to Reduce Organ Failure in Sepsis | Biotech Hunter | Biotech Hunter